Browse studies

Find your next paid study

90 recruiting studies matching your filters

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizum…

Ulcerative ColitisObesity or Overweight

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06937086

Family Members at INcreased-risk for Developing Inflammatory Bowel Disease (FIND-IBD)

First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developin…

Inflammatory Bowel Disease (IBD)Ulcerative Colitis (UC)IBD-unclassified (IBD-U)+10 more

Estimated

~$10 – $750

Massachusetts General HospitalNCT06655415

Phase 4

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, …

Ulcerative ColitisCrohn's Disease

A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (…

Ulcerative ColitisUlcerative Colitis ChronicInflammatory Bowel Diseases+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT04844606

Phase 3

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD…

Ulcerative ColitisCrohn's Disease

Estimated

~$10 – $7,500

TakedaNCT06405087

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

Background: Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include s…

Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis

Estimated

~$10 – $675

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07619547

Phase 3

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine)…

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to sever…

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07415044

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult parti…

Ulcerative Colitis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07186101

Real World Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention (MONITOR Study)

The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcome…

Inflammatory Bowel Disease (IBD)Crohn's DiseaseUlcerative Colitis

Estimated

~$10 – $750

Mercy Medical CenterNCT06750731

Remote eligible

A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut

This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal …

Inflammatory Bowel DiseaseUlcerative ColitisChrohn's Disease

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001184

Phase 2

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary g…

Ulcerative ColitisInflammatory Bowel DiseasesColitis+1 more

Estimated

~$10 – $8,750

Spyre Therapeutics, Inc.NCT07012395